Status:

COMPLETED

A Study of LY3209590 in Participants With Type 2 Diabetes

Lead Sponsor:

Eli Lilly and Company

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

18-70 years

Phase:

PHASE1

Brief Summary

This study will evaluate the safety and tolerability of LY3209590 when given by injection under the skin to participants with type 2 diabetes. It will also investigate how the body processes the study...

Eligibility Criteria

Inclusion

  • Participants with Type 2 Diabetes Mellitus (T2DM) for at least 1 year
  • Have a glycated hemoglobin (HbA1c) greater than or equal to (≥) 7.0 percent (%) to less than or equal to (≤) 10.5% at screening
  • Have had no episodes of severe hypoglycemia in the past 6 months
  • Are on stable basal insulin (neutral protamine Hagedorn insulin suspension \[NPH\] insulin, insulin glargine \[U100 or U300\], or insulin detemir) with or without metformin, dipeptidyl peptidase IV (DPP-IV) inhibitors, sulfonylureas, and sodium-glucose co-transporter 2 (SGLT-2) inhibitors, at a stable dose for at least 3 months before screening

Exclusion

  • Have significant lipohypertrophy in the target abdominal injection
  • Have a history of renal impairment
  • Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives (parents, siblings, or children)
  • Have proliferative retinopathy or maculopathy and/or severe neuropathy
  • Any significant changes in insulin regimen and/or unstable blood glucose control within the past 3 months prior to screening
  • Require daily insulin treatment less than (\<) 0.15 unit/kilogram (U/kg) per body weight
  • Are treated with a continuous subcutaneous insulin infusion (CSII) pump
  • Currently receiving degludec insulin therapy, or have been treated with degludec within the past 90 days

Key Trial Info

Start Date :

January 3 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 3 2018

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT03367377

Start Date

January 3 2018

End Date

October 3 2018

Last Update

December 11 2018

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Miami Research Associates

South Miami, Florida, United States, 33143

2

High Point Clinical Trials Center

High Point, North Carolina, United States, 27265

3

LMC Endocrinology Centres Ltd.

Toronto, Ontario, Canada, M4G 3E8